ABOUT US

WebenPharma is a biopharmaceutical company focusing on the discovery, development and commercialization of targeted small molecule drugs to treat cancer patients. Our programs exclusively target small molecule compounds that are potentially first-in-class drugs having little or no competition, or demonstrating a competitive advantage over drugs currently on the market or in clinical development.

Our lead product candidate under active development is WB001, a derivative of a well-known anti-tumor natural product. WB001 displays superior therapeutic index over the parent drug and has demonstrated excellent anti-tumor activities against a variety of human cancer cell lines such as KG-1A, MIA-Paca2 and H1975 in Xenograft mouse models. Our studies have clearly indicated that WB001 selectively targets c-myc gene positive tumors and could be effective for the treatment of pancreatic, lung, prostate, GI and other cancers. We have worldwide rights of WB001.